Free website traffic

COPENHAGEN, May 20 (Reuters) – Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia, the Danish company said on Wednesday.

Baxter had said Novo Nordisk’s newly launched haemophilia drug Novoeight infringed some of its patents, prompting an investigation from the U.S. International Trade Commision announced on Monday.

“Novo Nordisk strongly disagrees and has asked the court to intervene to settle the dispute,” Novo Nordisk said in a statement, referring to a case it brought in front of a New Jersey court in March.

(Reporting by Teis Jensen; Editing by David Holmes)

© Interactive Pharm 2022

Reach Out

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
Home
Quiz
Emporium
Medico
or

Log in with your credentials

or    

Forgot your details?

or

Create Account